STUDY PERIOD | ||||||
---|---|---|---|---|---|---|
 | Enrollment | Allocation and Baseline | Treatment | Follow-up | ||
Timepoint | Week -4 to -1 | Week -4 to 0 | Week 0 | Week 6 | Week 12 | Week 16 |
Screening, Enrollment, Allocation and Baseline Data | ||||||
 Screening for Eligibility | X |  |  |  |  |  |
 Informed Consent | X |  |  |  |  |  |
 Inclusion and Exclusion |  |  |  |  |  |  |
 CAPS-5 [16] | X |  |  |  |  | |
 SCID [17] | X |  |  |  |  |  |
 DES-II [18] | X |  |  |  |  |  |
 DRRI [19] | X |  |  |  |  |  |
 CES [20] | X |  |  |  |  |  |
 Narrative-Exposure, Effects on Health and with Treatment (unpublished) |  | X |  |  | X |  |
 LEC [21] | X |  |  |  |  |  |
 ACE [22] |  | X |  |  |  |  |
 MoCA [23] | X |  |  |  |  |  |
 Allocation |  | X |  |  |  |  |
Interventions | ||||||
 Verum Acupuncture |  |  |  |  | ||
 Sham Acupuncture |  |  |  |  | ||
Assessments: Primary Outcomes | ||||||
 CAPS-5 Severity Score [16] |  | X |  | X | X | X |
 PCL-5 [24] |  | X |  | X | X | X |
Assessments: Secondary Outcome | ||||||
 PPR (startle response) |  | X |  | X | X | X |
Assessments: Exploratory | ||||||
 BDI – II [25] |  | X |  | X | X | X |
 HAM-A [26] |  | X |  | X | X | X |
 NMCL – SOM [27] |  | X |  | X | X | X |
 PSQI [28] |  | X |  | X | X | X |
 VR-12 [29] |  | X |  | X | X | X |
 EDS [30] |  | X |  | X | X | X |
 McGill [31] |  | X |  | X | X |  |
 Southampton [32] |  |  | Bi-weekly |  | ||
 PPR (HR, HRV, SCR) |  | X |  | X | X | X |
Assessments: Safety and Control | ||||||
 AQ [33]. |  |  | Weekly | X | X | |
 BDI – II items 9, 11, 17 |  |  | Weekly | X | X | |
 Satisfaction with Care and Provider Scale (Unpublished) |  |  |  |  | X | X |
 Intercurrent Health Resource Use Inventory (unpublished) |  | X |  |  | X | X |
Assessments: Fidelity and Credibility | ||||||
 Treatment Fidelity Assessment (Unpublished) |  | selected |  |  |  |  |
 CRS [34] |  | selected | session 2 | session 24 |  |  |